A recent SPECTRUM article discussed the FDA’s ‘breakthrough device’ designation for a hair-based diagnostic test for autism. The test is called StranDx, and it was developed by Linus Biotechnology Inc., a provider of precision exposome sequencing. StranDx analyzes the levels of chemicals in a child’s hair for a snapshot of their ‘exposome,’ which includes their environmental exposures and how they regulate certain essential nutrients. This sheds light on how a child’s physiology responds to their environment, which can predict the chances of autism.
FDA Grants ‘Breakthrough Device’ Status to Hair-Based Autism Test
The test analyzes chemical levels in a strand of a child’s hair to predict their chances of having autism.
Jan 21, 2022
Recommended
Recommended
Sustainable Healthcare Packaging Solutions That Work
Industry leaders share proven strategies for reducing packaging emissions by up to 70% while meeting safety and regulatory requirements.
Read More
List: Digitalization Companies From PACK EXPO
Looking for CPG-focused digital transformation solutions? Download our editor-curated list from PACK EXPO featuring top companies offering warehouse management, ERP, digital twin, and MES software with supply chain visibility and analytics capabilities—all tailored specifically for CPG operations.
Download Now
Downloads
